Amgen to Invest $200M in AI-Driven Innovation Hub in India

Amgen, one of the United States' leading pharmaceutical companies, will invest nearly $200 million this year alone in its brand-new technology hub in southern India, with investments to come later, CEO Robert Bradway declared on Monday.

The firm initially announced its intention to set up a "technology and innovation" center in India last year, with a view to developing the application of artificial intelligence and data science to support the creation of new drugs.

"We have wanted for a long time to expand Amgen's presence in India and that time has come. Amgen is investing an initial $200 million in this centre in 2025 and plan to make additional significant investments in future years," Bradway said.

Based in Hyderabad, the center is likely to have about 2,000 employees by the end of the year, with about 300 employees already hired, said Som Chattopadhyay, Amgen's national executive for India.

Hyderabad will also welcome the BioAsia conference this week, with guest speakers from such big pharma players as Amgen, Eli Lilly, Novartis, and some leading Indian drug companies.

In the meantime, India and the United States recently agreed to start negotiations for an early trade agreement and settlement of tariff issues after U.S. President Donald Trump met with Indian Prime Minister Narendra Modi.

"One significant outcome (of the talks) was the launch of the U.S.-India trust initiative, which is to promote collaboration in critical and emerging technologies, something that both our countries really need," U.S. Consul General in Hyderabad, Jennifer Larson, said.

Trump has signaled an intention to add tariffs of "25 percent or more" on pharmaceutical imports—a step that can severely affect Indian pharma companies, as America is their largest market for generics.